STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3351 by analyst upside · 2026-06-27
RVMD
Revolution Medicines, Inc.
Healthcare · Market Cap $39B · P/E 0x
ANALYST PRICE TARGET
+3.6%
implied upside to consensus target
Current Price $182.08
Consensus Target $188.57
Bull Target $263.0
Bear Target $151.0
Analysts Covering 21
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
17
Hold
0
Sell
0
52-Week Low $34.0
52-Week High $184.39
YTD Return +130.4%
FUNDAMENTALS
Market Cap $39B
P/E Ratio (TTM) N/A
Forward P/E -31.9x
EPS (TTM) $-7.27
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $34.0
52-Week High $184.39
Current Price $182.08
Bear Target $151.0
Bull Target $263.0
● Now $182.08 ● Target $188.57
TRADING DATA
Avg Volume 3.3M
YTD Return +130.4%
Analyst Count 21
Consensus Buy
Upside to Target +3.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Revolution Medicines, Inc. (RVMD) is currently trading at $182.08 with a Wall Street consensus price target of $188.57, implying potential upside of 3.6% over the next 12 months. 21 analysts currently cover RVMD, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $263.0, while the most cautious has a target of $151.0.

RVMD operates in the Healthcare sector with a market capitalisation of $39B. The stock is up 130.4% year-to-date and is currently trading near the upper end of its 52-week range of $34.0 – $184.39.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RVMD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Evercore ISI Group — Reiterated
Outperform → Outperform 2026-06-10 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-06-02 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-06-01 31% win rate (48 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2026-06-01 14% win rate (7 calls)
Bernstein ● Initiated
Market Perform 2026-05-22 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-05-07 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-05-07 62% win rate (8 calls)
Wedbush — Reiterated
Outperform → Outperform 2026-05-07 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
69
out of 100
Coverage depth
24/30
Consensus clarity
18/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →